Bio-Techne (NASDAQ: TECH) is sliding after releasing fiscal third-quarter 2026 results that came in lighter than expected on the top line, triggering a negative re-pricing of near-term growth expectations. The company posted net sales of $311.4 million, down 2% year over year, which landed below consensus expectations cited by market reports and helped drive the selloff. (stocktitan.net)

The revenue miss is being tied to softer demand conditions for research-linked spending, with pressure described as connected to reduced U.S. academic funding, weighing on demand for products used in drug development workflows. On top of the macro/demand headwind, the quarter faced tough year-ago comparisons tied to prior-year GMP fast-track orders and the timing of large commercial supply shipments, which dampened reported and organic growth. (boursorama.com)

Despite the sales shortfall, profitability metrics were mixed: GAAP EPS rose to $0.32, while adjusted EPS was reported at $0.53 in company-focused recaps of the release. Investors are weighing whether the margin performance can offset the apparent demand softness, especially if academic-related pressure lingers and if shipment timing continues to create quarter-to-quarter volatility. (tipranks.com)

Near-term focus is on management commentary about demand trends across research end markets and whether order patterns improve as funding conditions normalize. Investors will also watch for any updated outlook language and signs that year-ago comparison headwinds (fast-track GMP orders and shipment timing) fade in coming quarters, which could reduce revenue variability. (chartmill.com)